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Background: Factor V is activated to factor Va to interact with factor Xa.
Results: Elimination of nine amino acids from the B domain results in binding of unactivated factor V to factor Xa.
Conclusion: Amino acids 1000 –1008 of factor V prevent unwanted prothrombinase assembly.
Significance: A short peptide sequence from the B region is a regulatory domain for the generation of factor Va procoagulant activity.
Single chain factor V (fV) circulates as an Mr 330,000 quiescent pro-cofactor. Removal of the B domain and generation of
factor Va (fVa) are vital for procoagulant activity. We investigated the role of the basic amino acid region 1000 –1008 within
the B domain of fV by constructing a recombinant mutant fV
molecule with all activation cleavage sites (Arg709/Arg1018/
Arg1545) mutated to glutamine (fVQ3), a mutant fV molecule
with region 1000 –1008 deleted (fV⌬B9), and a mutant fV molecule containing the same deletion with activation cleavage sites
changed to glutamine (fV⌬B9/Q3). The recombinant molecules
along with wild type fV (fVWT) were transiently expressed in
COS-7L cells, purified, and assessed for their ability to bind factor Xa (fXa) prior to and following incubation with thrombin.
The data showed that fVQ3 was severely impaired in its interaction with fXa before and after incubation with thrombin. In
contrast, KD(app) values for fV⌬B9 (0.9 nM), fVa⌬B9 (0.4 nM), and
fV⌬B9/Q3 (0.7 nM) were similar to the affinity of fVaWT for fXa
(0.3 nM). Two-stage clotting assays revealed that although fVQ3
was deficient in its clotting activity, fV⌬B9/Q3 had clotting activity comparable with fVaWT. The kcat value of prothrombinase
assembled with fV⌬B9/Q3 was minimally affected, whereas the
Km value of the reaction was increased 57-fold compared with
the Km value obtained with prothrombinase assembled with
fVaWT. These findings strongly suggest that amino acid region
1000 –1008 of fV is a regulatory sequence protecting the organisms from spontaneous binding to fXa and unnecessary prothrombinase complex formation, which in turn results in catastrophic physiological consequences.

Human factor V (fV)3 circulates in whole blood as a single
chain inactive pro-cofactor with an Mr 330,000 consisting of
multiple domains (A1-A2-B-A3-C1-C2) at a concentration of
20 nM (1). In the presence of a procoagulant membrane surface,
fV undergoes limited proteolysis to become an active participant in the coagulation cascade (1–3). Single chain fV does not
bind fXa, and proper removal of the B domain is vital to generate procoagulant activity (4, 5). fV is activated to factor Va (fVa)
by thrombin, fXa, and a protease extracted from a snake venom
(RVV-V activator) (1, 2). The sequential cleavage of fV by
thrombin at Arg709, Arg1018, and Arg1545 is physiologically necessary for generation of procoagulant activity (Fig. 1) (6). Following the removal of the heavily glycosylated B domain, the
light (Mr 74,000) and heavy (Mr 105,000) chains of fVa associate
in the presence of divalent metal ions into a noncovalently
attached heterodimer that functions as a cofactor in the prothrombinase complex (1, 7–9). fVa binds to fXa on a phospholipid membrane in the presence of divalent metal ions to form
the prothrombinase complex. Appropriate binding of fVa to
fXa during prothrombinase assembly and function is essential
for the proper and timely activation of the substrate prothrombin (5, 10, 11).
Removal of a considerable quantity of amino acids from fV to
produce an active cofactor molecule has been a major area of
study in the expression of recombinant fVa coagulant activity
(12–15). Partial to full B domainless fV derivatives have been
used to determine the purpose of the B domain and how it
participates in the regulation of the coagulation cascade. Kane
et al. (13) used a recombinant B domainless fV derivative that
was missing 680 amino acids (factor V(des-811–1491) or
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FIGURE 1. FV structure and mutant molecules. The pro-cofactor fV is composed of three A domains (red), a connecting B domain (yellow), and two C domains
(blue). fV undergoes three sequential cleavages by thrombin at Arg709, Arg1018, and Arg1545 to generate the active cofactor fVa. The deletion within the basic
homologous region of the B domain (amino acid residues 1000 –1008) is coupled with mutations at each one of the thrombin activation sites (Arg 3 Gln). The
recombinant mutant fV molecules created are indicated with specific designations used throughout this work.

FV-810). FV(des-811–1491) was able to express full coagulant
activity after proteolysis with RVV-V or thrombin. Similar
results were obtained with other recombinant fV derivatives
that were missing more than 50% of the B domain (15). With
the introduction of 378 or more amino acids back into this
region, other mutants became functionally deficient in clotting
activity and were comparable with the pro-cofactor molecule
(15). However, one recombinant molecule, factor V-956, which
was constructed without a specific region rich in basic amino
acids, had an intermediate activity. In the portion 963–1008, 18
of 46 amino acids were identified to be either lysine or arginine,
and 7 of these 18 amino acids are located in a row within the
region encompassing amino acids 1000 –1008 (Fig. 2) (15).
Although the B domain of fV does not share homology with
factor VIII or other known proteins, a comparative sequence
analysis of fV among mammals revealed that a stretch of amino
acids within a highly basic region was consistently found in
other species attesting to its physiological significance (Fig. 2).
Thus, the basic amino acid sequence 1000 –1008 of the B
domain of fV could play a part in inhibiting binding between
fXa and the heavy and/or light chain of fVa (Fig. 1) (16 –21). It is
noteworthy that we and others have demonstrated that the
binding site for fXa located on the heavy chain of the cofactor is
composed of a majority of acidic amino acids (17–22). Proteolysis of fV and removal of this basic amino acid region may allow
for the release of electrostatic restraints and the ability for unactivated fV to show procoagulant activity (i.e. interact with fXa
on a procoagulant membrane surface and activate prothrombin). Thus, this mechanism that controls the pro-cofactor
would be comparable with certain aspartic and cysteine proteases (23).
This work was undertaken to explore the significance of the
basic amino acid sequence that is almost identical among a wide
range of species (Fig. 2) and to understand its role in maintaining fV in a quiescent state. The aim of our study was to verify the
hypothesis that amino acid region 1000 –1008 provides a specific regulatory sequence that controls the binding of fVa to fXa
and thus controls cofactor activity. For this purpose, we constructed several recombinant fV molecules to be assessed for
DECEMBER 27, 2013 • VOLUME 288 • NUMBER 52

their cofactor and clotting activities as well as for the direct
binding to fXa. The results presented herein solidify the notion
that only a short and discrete region from the B domain of fV is
crucial and is required to keep the pro-cofactor in a quiescent
state.

EXPERIMENTAL PROCEDURES
Materials—Diisopropyl fluorophosphate, o-phenylenediamine dihydrochloride, and Coomassie Blue R-250 were purchased from Sigma. fV-deficient plasma was from Research
Protein Inc. (Essex Junction, VT). Secondary anti-mouse and
anti-sheep IgG coupled to peroxidase was purchased from
Southern Biotechnology Associates, Inc. (Birmingham, AL).
L-␣-Phosphatidylserine and L-␣-phosphatidylcholine were
obtained from Avanti Polar Lipids (Alabaster, AL). Chemiluminescent reagent ECL⫹ and heparin-Sepharose were obtained
from Amersham Biosciences. Normal reference plasma and the
chromogenic substrate H-D-hexahydrotyrosyl-alanyl-arginylp-nitroanilide diacetate (Spectrozyme-TH) were purchased
from American Diagnostica Inc. (Greenwich, CT). RecombiPlasTin used in the clotting assays was purchased from Instrumentation Laboratory Co. (Lexington, MA). The reversible
fluorescent ␣-thrombin inhibitor dansylarginine-N-(3-ethyl1,5-pentanediyl)-amide (DAPA), human thrombin, human
prothrombin, and active site-blocked human meizothrombin
(obtained following digestion of prothrombin with the purified
component from the venom of the snake Echis carinatus, FPRmeizothrombin) were purchased from Hematologic Technologies Inc. (Essex Junction, VT). Human fXa was purchased from
Enzyme Research Laboratories (South Bend, IN). Human factor V cDNA was obtained from American Type Tissue Collection (ATCC 40515 pMT2-V, Manassas, VA). All restriction
enzymes were obtained from New England Biolabs (Beverly,
MA). All molecular biology and tissue culture reagents, specific
primers, and medium were purchased from Invitrogen or as
indicated. Recombinant prothrombin rMZ-II that has only one
cleavage site for fXa (i.e. Arg320) and prothrombin rP2-II that
has only one cleavage site for fXa (i.e. Arg271) were prepared and
purified as described previously (24). Human fV monoclonal
JOURNAL OF BIOLOGICAL CHEMISTRY

37027

Dynamic Regulatory Effects of Specific Factor V Amino Acids

FIGURE 2. Comparison of the basic region of amino acid sequences 1000 –1008 from fV B domain among multiple species. The databases GenBankTM
and NCBI Trace Archive were used to derive sequences of fV among various mammalian species to compare homology. The basic amino acid sequence of
interest is shown in red. The following species are included (from top to bottom): Homo sapiens, human; Pan troglodytes, chimpanzee; Pongo abelii, Sumatran
orangutan; Bos taurus, cattle; Sus scrofa, pig; Callithrix jacchus, white-tufted-ear marmoset; Rattus norvegicus, Norway rat; Mus musculus, western European
house mouse.

antibodies (␣HFVHC17 and ␣HFVLC9) used for immunoblotting experiments and monoclonal antibody ␣HFV1 coupled to
Sepharose used to purify plasma and recombinant factor V
molecules were provided by K. G. Mann (Dept. of Biochemistry,
University of Vermont, Burlington). Plasma fV (fVplasma) was
purified as described previously (25, 26).
Construction of Recombinant fV Molecules—Recombinant
fV molecules with mutations, fVRQQ, fVQ3, fV⌬B9, and fV⌬B9/Q3,
were constructed using the QuikChange XL site-directed
mutagenesis kit from Stratagene. We generated all cleavage
activation mutants by changing arginine to glutamine. fVQ3 was
constructed using the following mutagenic primers: 5⬘-GCA
TTA GGA ATC CAG TCA TTC CGA AAC-3⬘ (sense) and
5⬘-GTT TCG GAA TGA CTG GAT TCC TAA TGC-3⬘ (antisense) (corresponding to the R709Q mutation); 5⬘-CCT TTA
TCT CCG CAG ACC TTT CAC CCT C-3⬘ (sense) and 5⬘-G
AGG GTG AAA GGT CTG CGG AGA TAA AGG-3⬘ (antisense) (corresponding to R1018Q mutation); and 5⬘-GCA TGG
TAC CTC CAA AGC AAC AAT GG-3⬘ (sense) and 5⬘-CC
ATT GTT GCT TTG GAG GTA CCA TGC-3⬘ (antisense)
(corresponding to R1545Q mutation). fV⌬B9 was constructed
using the mutagenic primers 5⬘-CTG AAG AAA AGC CAG
TTT CTC ATT CAC ACA CAC CAT GCT CCT TTA TCT
CCG-3⬘ (sense) and 5⬘-CGG AGA TAA AGG AGC ATG GTG
TGT GTG AAT GAG AAA CTG GCT TTT CTT CAG-3⬘
(antisense) (corresponding to the 1000KTRKKKKEK1008 deletion). To construct fV⌬B9/Q3, the same primers were used, and
fVQ3 was used as the template in the PCR. To construct fVRQQ,
a similar methodology was employed with the mutagenic
primers for R1018Q 5⬘-CCTTTATCTCCGCAGACCTTTCACCCTC-3⬘ (forward) and 5⬘-GAGGGTGAAAGGTCTGCGGAGATAAAGG-3⬘ (reverse) and the mutagenic primers
for R1545Q 5⬘-GCATGGTACCTCCAAAGCAACAATGG-3⬘
(forward) and 5⬘-CCATTGTTGCTTTGGAGGTACCATGC-3⬘ (reverse). All mutations were confirmed by DNA
sequencing (DNA Analysis Facility, Dept. of Molecular Cardiology at The Lerner Research Institute, Cleveland Clinic, Cleveland, OH).
Transient Transfection, Purification, and Assay of Recombinant fV Molecules—Purified wild type fV (fVWT), fV⌬B9, fV⌬B9/Q3,
fVRQQ, and fVQ3 plasmids were transfected into COS-7L
cells with FuGENE 6 (Roche Diagnostics), according to the
manufacturer’s instructions as described extensively by our lab-
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oratory (17, 18). A 4-ml column of monoclonal antibody
␣HFV1 coupled to Sepharose was used to purify recombinant
proteins as extensively described previously (27). To avoid
repeated freeze-thaw cycles, small aliquots of the purified proteins were stored at ⫺80 °C. Clotting assays using fV-deficient
plasma and Western blotting with monoclonal and polyclonal
antibodies were used to determine the activity and integrity of
the recombinant fV molecules as described previously (25, 28).
Thrombin was used for the activation of fV and was inhibited
by the addition of PMSF. Any residual thrombin used in activation that could potentially contribute to our experimental data
were eliminated in the reaction mixtures by the addition of
DAPA. All experimental procedures were thoroughly and
extensively described previously (17, 18, 27, 29).
Determination of the Concentration of the Recombinant fV
Molecules—The concentration of fV was determined with an
ELISA as extensively described (17, 18, 27, 28). The absorbance
at 490 nm was monitored using an Amersham Biosciences
THERMOMAX microplate reader. Because of slight differences in time of incubation with the substrate, in every experiment a plasma fV standard (serial dilutions of purified plasma
fV) was run, and all values obtained with the recombinant molecules were compared with the plasma fV standard values
within the same 96-well plate. No comparison in concentration
was made between recombinant molecules from one plate to
another. The determination of the concentration of the recombinant molecules was performed by averaging the value found
for each sample run in triplicate.
Gel Electrophoresis and Western Blotting—SDS-PAGE analyses were carried out using 4 –12% gradient gels or 9.5% gels
following reduction with 2% ␤-mercaptoethanol, according to
the method of Laemmli, and the protein was visualized by being
stained with Coomassie Brilliant Blue R-250, followed by
destaining in a solution of methanol, acetic acid, and water (30).
In several experiments, the protein was transferred to polyvinylidene difluoride (PVDF) membranes following a modification of the method described by Towbin et al. (31). The membrane transferred proteins were incubated with monoclonal
and polyclonal antibodies specific to fV heavy/light chains, and
the protein was visualized by immunoreactive chemiluminescence using ECL Plus reagents (GE Healthcare).
Kinetic Titrations of Prothrombinase—A discontinuous assay
was used to assess the ability of the recombinant fV molecules
VOLUME 288 • NUMBER 52 • DECEMBER 27, 2013
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to assemble in the prothrombinase complex and bind to the
enzyme (18). Briefly, fV variants were assayed after (fVa) and
before (fV) the activation with thrombin. To determine the dissociation constant (KD(app)) between the fV/fVa molecules and
fXa, we prepared separate reaction mixtures that contained
PCPS vesicles (where PCPS indicates small unilamellar phospholipids vesicles composed of 75% L-␣-phosphatidylcholine
and 25% L-␣-phosphatidylserine (w/w)) (20 M), DAPA (3 M),
a limiting fXa concentration (15 pM) and varying concentrations of the recombinant fVa species (30, 60, 125, 250, and 500
pM and 1, 2.5, 5, and 10 nM). The reaction was initiated with a
constant and saturating amount of prothrombin (1.4 M). At
selected time intervals into each reaction (20, 40, and 60 s),
aliquots were added separately to 80 l of quench buffer in a
96-well microtiter plate, and the primary thrombin plots (the
rate of thrombin generation as a function of time) were measured using Spectrozyme-TH (0.4 mM). The KD(app) of each
recombinant fVa species for fXa was then calculated by plotting
the data as thrombin activity (nM IIa/min) as a function of the
fV/fVa concentration to the equation representing a one binding site model using the software Prism威 (GraphPad, San
Diego). All experiments were performed at least in duplicate,
and the goodness of fit (R2) for the model (equation) tested is
provided in each table. In addition, and to avoid any artifacts or
inter-experimental variation, all recombinant mutant fV/fVa
molecules were assayed at the same time and with the same
reagents as the wild type or plasma cofactor molecule, on the
same 96-well microtiter plate. The KD(app) obtained directly
from the graphs was used to calculate the amount of fV/fVa
necessary to saturate fXa using the quadratic equation extensively described in detail elsewhere (32–34).
To determine the kinetic constants (Km and kcat) of prothrombinase, assays were performed using limited amounts of
fXa (10 pM) in the presence of a fixed (saturating) amount of
various recombinant fV/fVa molecules (20 – 80 nM) while varying the prothrombin concentration. The reaction was initiated
by adding increasing concentrations of prothrombin (25, 50,
100, 250, 500, and 750 nM and 1, 2, and 4 M) to the mixture
already containing a constant amount of prothrombinase
determined as described above to be ⬃10 pM using the known
KD(app) for each variant and the quadratic equation described
previously (32, 33). At selected time intervals into each reaction, aliquots were added separately to 80 l of quench buffer in
a 96-well microtiter plate, and the primary thrombin plots (initial rate of thrombin generation) were obtained with the chromogenic substrate Spectrozyme-TH. The data were plotted to
the Michaelis-Menten equation as nM IIa/min as a function of
prothrombin and analyzed with the software Prism威. All experiments were performed at least in duplicate, and the goodness
of fit (R2) for the model tested (Michaelis-Menten equation) is
provided in each table. To avoid any artifacts or inter-experimental variation, all recombinant mutant fV/fVa molecules
were assayed at the same time and with the same reagents as the
wild type or plasma cofactor molecule, on the same 96-well
microtiter plate. All kinetic constants reported in the tables
were derived directly from the graphs.
Stabilization of the Transition State—Prothrombinase is an
enzyme composed of fVa (regulatory subunit) and fXa (cataDECEMBER 27, 2013 • VOLUME 288 • NUMBER 52

lytic subunit) assembled on a membrane surface. Any perturbation in the interaction between the two molecules caused by
a mutation may influence or modify the stability of the catalytic
site of the enzyme and can be measured by the change in the
transition-state stabilization of free energy for prothrombin
activation as described (35–39). Thus, the consequence of the
mutations in fVa affecting fXa catalytic efficiency can be measured relative to the change in transition-state stabilization free
energy (⌬⌬G‡) of the enzyme. To assess whether the deletion in
the B region affects the stabilization of the transition state, separate free energies associated with the catalytic efficiency of
prothrombinase must be measured as follows: ⌬GWT, the functional free energy in prothrombinase assembled with fVaWT;
⌬G⌬B9/Q3, the functional free energy in prothrombinase assembled with fV⌬B9/Q3; and ⌬GRQQ, the functional free energy in
prothrombinase assembled with fVaRQQ. The perturbation to
the function of the enzyme (prothrombinase) caused by a mutation in its regulatory subunit (fVa) affecting the transition state
can be defined as shown in Equations 1 and 2,
⌬⌬G ⌬B9/Q3 ⫽ ⌬G⌬B9/Q3 ⫺ ⌬GWT

(Eq. 1)

⌬⌬G RQQ ⫽ ⌬GRQQ ⫺ ⌬GWT

(Eq. 2)

The specificity constant (also known as catalytic efficiency or
second-order rate constant), which is defined by the ratio kcat/
Km, does not measure the rate of an enzyme per se, but rather it
measures the efficiency of an enzyme toward different substrates or the efficiency of different enzymes or mutant enzyme
molecules versus a common substrate (36 –38). Thus, it is generally used to evaluate the effectiveness of different enzymes to
one another when assessed against the same substrate. Because we
are measuring prothrombinase activity assembled in the presence
of various fV/fVa molecules against the same substrate (prothrombin), the changes in transition-state stabilization free energy
(⌬⌬G‡) during catalysis caused by the mutations in fV/fVa can be
calculated from Equations 3 and 4,
‡
⫽ ⫺RT ln共共kcat/Km兲⌬B9/Q3/共kcat/Km兲WT兲
⌬⌬G WT¡⌬B9/Q3

(Eq. 3)
‡
⌬⌬G WT¡RQQ
⫽ ⫺RT ln共共kcat/Km兲RQQ/共kcat/Km兲WT兲

(Eq. 4)

where R is the universal gas constant (2 cal䡠 K⫺1䡠mol⫺1); T is the
absolute temperature in Kelvin (298 K in all our experiments);
kcat is the turnover number, and Km is the Michaelis-Menten
constant for prothrombinase assembled with either wild type
fVa or mutant fV/Va molecules.
Studies of the Pathway for Prothrombin Activation by Gel
Electrophoresis—Reaction mixtures were incubated with prothrombin containing 20 M PCPS, 8 M DAPA, and various
concentrations of fVaWT, fVa⌬B9, and fVaRQQ (incubated with
thrombin, 2 nM) and fVQ3 and fV⌬B9/Q3 in TBS with Ca2⫹.
Before the addition of fXa (0.5 nM) and the start of the reaction,
a zero point was taken. Aliquots of the reaction mixture were
removed at selected time points and treated as described previously in detail (18, 40, 41). Prothrombin consumption was
visualized by gel electrophoresis and quantified by using densitometry as described previously (40, 41). For the studies of
JOURNAL OF BIOLOGICAL CHEMISTRY
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prothrombin cleavage and activation by factor Xa alone, a
similar protocol was used as described (41). Briefly, reaction
mixtures containing 1.4 M prothrombin, 20 M PCPS, and 8
M DAPA were incubated for 5 min, and the reaction was
initiated with the addition of factor Xa (0.5–1 nM) at room
temperature over a 1-h time course. Aliquots (50 l) from
the reaction were removed at selected time intervals (as indicated in the legend to the figures), treated as described previously
(40), and analyzed using 9.5% SDS-PAGE. Prothrombin consumption rates were calculated as described previously in detail (40, 41).
Studies to Control Recombinant fV Back Activation during
Prothrombin Activation Assays—Wild type fVa and mutant
fV/fVa molecules were assessed for activation throughout a
prothrombin activation assay as described. Before the incubation with fXa (0.5 nM) into the reaction mixture, a zero point
was taken. A sample was also taken following a 1-h incubation
with fXa and all the components of prothrombinase. Aliquots
of the reaction mixture containing recombinant fV/fVa molecules (1 g) were removed and immediately diluted into 2-fold
the volume of 0.2 M acetic acid and concentrated by centrifugation as described (40). The pellets were dissolved in a 0.1 M Tris
base, pH 6.8, and 1% SDS. After reconstitution, the samples
were subjected to 4 –12% gradient gels and probed for activation fragments using Western blotting techniques as described
previously (41, 42).

RESULTS
Transient Expression and Analysis of Recombinant fV
Molecules—To investigate the importance of amino acid region
1000 –1008 of the B domain of fV, we constructed four mutant
molecules. We prepared recombinant fVRQQ, fV⌬B9, fVQ3, and
fV⌬B9/Q3. All recombinant molecules were expressed as fulllength derivatives in mammalian cells and were purified to
homogeneity by immunoaffinity chromatography as described
previously in great detail by our laboratory (27). A typical routine quality control method performed in our laboratory before
all experiments is to assess recombinant fVWT and mutant molecules for their integrity following activation by thrombin.
Fig. 3 illustrates the composition of the recombinant molecules before and after incubation with thrombin following
staining with silver. To rule out any contribution of minute
impurities to cofactor activity, we compared the clotting
activities of fVaWT and fVa purified from pooled fresh frozen
normal plasma (fVaplasma). All data obtained from purified
fVaplasma and recombinant fVaWT were comparable. fVaWT
activated with thrombin had similar cofactor activity when
compared directly with fVaplasma (Table 1). It is also important to note that the data obtained with purified recombinant fVaWT is comparable with recombinant fVa molecules
used in conditioned media (17, 18). Thus, any small impurities that may be present in our fV preparations do not have
any impact on cofactor activity. Additionally, purified
recombinant fV molecules with all activation sites changed
to glutamine are unable to be cleaved and form active cofactors (Fig. 3, panels C and F). Finally, the activation quotient
of fVQ3 that measures the ratio of activity after and before
deliberate activation by thrombin was close to 18, demon-
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FIGURE 3. Electrophoretic analyses of the purified recombinant molecules. Purified recombinant fVWT and purified recombinant fV molecules
fV⌬B9, fV⌬B9/Q3, fVRQQ, and fVQ3 were incubated with thrombin as described
under “Experimental Procedures” and analyzed by SDS-PAGE followed by
staining with silver. Panels A–C show the molecules before (⫺) and after activation by thrombin (⫹). Panels D–F show the molecules before (0 min) and
after incubation with thrombin for 10 and 20 min. The identity of each fV
molecule is shown below each panel. HC, heavy chain; LC, light chain.

strating very little unintentional activation of fVQ3 during
the purification procedures (25).
As shown in Fig. 3, recombinant fV⌬B9/Q3 and fVQ3 molecules having all activation sites changed to glutamine (panels C
and F, respectively) were resistant to thrombin cleavage and
activation, whereas fVWT and fV⌬B9 following incubation with
thrombin exhibited the normal fragments representing the
heavy and light chains of the active cofactor (panels A, B, and
D). In addition, fVRQQ produced only the expected heavy chain
of the cofactor and an Mr 220,000 intermediate following
extended incubation with thrombin (Fig. 3, panel E). A twostage clotting assay was first used to assess cofactor activity of
the recombinant molecules. Using similar experimental conditions, fVQ3 was found to have clotting activity 17.4-fold lower
than fVaWT. In addition, although fVQ3 is severely impaired in
its clotting activity, unexpectedly fV⌬B9/Q3 had clotting activity
comparable with fVaWT and fVaRQQ (Table 1). These data demonstrate that amino acid region 1000 –1008 is important for the
regulation of optimal clotting activity of fVa. These data also
show that cleavage at Arg709 alone is sufficient to recover most
fVa clotting activity.
Kinetic Analyses of Recombinant fV Molecules—We have
observed thus far that deletion of amino acid region 1000 –1008
VOLUME 288 • NUMBER 52 • DECEMBER 27, 2013
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TABLE 1
Functional properties of recombinant fV molecules
Factor Va
species

Clotting
activitya
units/mg

fVaWT
fVaplasma
fVQ3
fV⌬B9/Q3
fVaRQQ

3590 ⫾ 300
3200 ⫾ 274
206 ⫾ 37
3110 ⫾ 65
2370 ⫾ 465

Decreaseb
-fold

1.1
17.4
1.1
1.5

KD(app)c

R2/points studied
for KD(app)d

M

nM

0.28 ⫾ 0.03
0.51 ⫾ 0.06
5.5 ⫾ 7.15
0.73 ⫾ 0.08
0.92 ⫾ 0.27

Kme

0.92/80
0.99/10
0.37/30
0.93/80
0.90/20

kcate,f
min

⫺1

Decreaseg

kcat/Km
⫺1 ⫺1
M 䡠s

⫻ 10

6

-fold

0.14 ⫾ 0.01
0.17 ⫾ 0.02

1993 ⫾ 36
2030 ⫾ 45

237
199

1.2

8.0 ⫾ 3.3
0.18 ⫾ 0.04

452 ⫾ 140
655 ⫾ 33

0.94
61

252
4

a

Two-stage clotting assays of recombinant fV molecules were performed as described under “Experimental Procedures.”
The -fold decrease is the ratio of the clotting activity of fVaWT compared with the clotting activity of all other fV molecules. The ratio of clotting activity between fVaWT
and fVQ3 demonstrates that there is very little unintentional activation of fVQ3 (AQ ⫽ 17.4) (25).
c
The apparent dissociation constants of recombinant fV/fVa and plasma fVa molecules for plasma-derived fXa (KD(app)) were determined as described under “Experimental
Procedures” at limiting fXa concentrations (15 pM) according to the binding model assuming one binding site using the software Prism威. Apparent dissociation constants
were derived directly from the fitted data. The data shown represent average numbers from eight separate experiments performed with eight different preparations of
fVaWT, eight different preparations of fV⌬B9/Q3, three different preparations of fVQ3, and one preparation of fVaplasma.
d 2
R represents the goodness of fit to the equation describing the binding model assuming one binding site using the software Prism威. Points studied represent eight separate
graphs (10 measurements/graph) for experiments using fVaWT and fV⌬B9/Q3 employing eight different preparations of recombinant fV molecules. The KD(app) of fVQ3 for
fXa was obtained using three separate graphs with three different preparations of fVQ3, whereas the KD(app) of fVaplasma for fXa was obtained from one graph using one
preparation of fVplasma.
e
The Km and kcat values of prothrombinase assembled with saturating concentrations of plasma fVa and recombinant fV/fVa molecules were determined as described under
“Experimental Procedures” according to the Michaelis-Menten equation using the software Prism威. Kinetic constants were derived directly from the fitted data shown in
Fig. 6.
f
kcat ⫽ Vmax/关enzyme兴 (in the presence of fVa); the enzyme concentrations of prothrombinase (fXa-fV/fVa complex on the membrane surface in the presence of Ca2⫹) were
calculated based on the equations previously described in detail in the literature. Under the conditions employed herein, prothrombinase concentration was assumed to be
⬃10 pM (the fXa used was ⬎98% saturated with fVa).
g
The -fold decrease is the ratio of the specificity constant (kcat/Km) of prothrombinase assembled with fVaWT compared with the specificity constant of prothrombinase
assembled with fV⌬B9/Q3.
b

from the B region of fV results in a molecule that does not
require prior activation by thrombin to acquire optimum clotting activity. In contrast, a recombinant molecule without the
deletion but with all activation sites changed to glutamine
(fVQ3) was practically devoid of cofactor activity. It is thus possible that the nine amino acids deleted in this molecule (fV⌬B9/Q3)
are required to keep fV in a quiescent state and thus impair the
high affinity fVa-fXa interaction on the membrane surface
required for prothrombinase assembly and function. As a consequence, the ability of recombinant fV molecules to bind fXa
was studied next using purified reagents and a chromogenic
substrate assessing thrombin formation. The assay was performed under conditions of varying concentrations of recombinant fV/fVa molecules while using limiting concentrations of
fXa. This assay has been widely used in the coagulation field to
determine the KD(app) value for the fVa-fXa or factor VIIIafactor IXa interactions when the concentration of the cofactors
is sparse (recombinant molecules or plasma-derived cofactors
from various fV variants) (20, 21, 43– 46).
The results from the binding studies are shown in Fig. 4, and
the data extracted directly from the plots are reported in Table
1. Using this methodology, we have repetitively shown that the
KD(app) value of the bimolecular interaction between fVa and
fXa is similar to the KD(app) value established by several other
binding methods (6, 14, 18, 22, 47– 49). The data demonstrate
that fVQ3 was unable to interact with fXa (Fig. 4, open squares,
and Table 1). In contrast, the affinity of recombinant mutant
fV⌬B9/Q3 for plasma-derived fXa was similar to the affinity of
fVaWT or fVaplasma for the plasma-derived enzyme (Table 1 and
Fig. 4, filled squares and filled and open circles, respectively).
These results contradict recent findings (49) and demonstrate
that only a very limited stretch of nine amino acids within the B
domain of fV is required to sheath the interactive site(s) within
fV that are essential for its binding to plasma-derived fXa and as
a consequence keep the pro-cofactor in a quiescent state. Direct
comparison between the data obtained with prothrombinase
DECEMBER 27, 2013 • VOLUME 288 • NUMBER 52

FIGURE 4. Determination of the dissociation constant of recombinant
fV⌬B9/Q3 and fVQ3 for plasma fXa. Thrombin generation experiments were
carried out as described under “Experimental Procedures.” Prothrombinase
assembled with varying concentrations of recombinant purified fVQ3 is
depicted by open squares, prothrombinase assembled with purified recombinant fV⌬B9/Q3 by filled squares, and prothrombinase assembled with purified
recombinant fVaRQQ by filled triangles. Prothrombinase assembled with varying concentrations of recombinant purified fVaWT is depicted by filled circles,
and prothrombinase assembled with purified recombinant fVaplasma is
depicted by open circles. The solid lines represent a nonlinear regression fit
of the data using Prism姞 GraphPad software and the equation describing
the one binding site model. Titrations shown herein were performed with
multiple preparations of recombinant proteins as detailed in Table 1. The
kinetic constants derived directly from the plotted data are also reported
in Table 1. The assay was performed with fV/fVa species varying from 0 to
15 nM. However, for the easy plotting of the data, only points from 0 to 10
nM are shown.

assembled with fVaWT, fVaRQQ, and fVQ3 demonstrates that
under similar experimental conditions the initial cleavage at
Arg709 and the generation of the heavy chain alone resulted in a
molecule (fVaRQQ) that has a similar affinity for plasma fXa as
fVaWT or fVaplasma (Fig. 4, filled triangles, and Table 1).
JOURNAL OF BIOLOGICAL CHEMISTRY
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TABLE 2
Kinetic parameters of prothrombinase with increasing concentrations of purified mutant recombinant fV molecules
Recombinant
fV species
nM

fV⌬B9/Q3 (15)
fV⌬B9/Q3 (30)
fV⌬B9/Q3 (60)d
fV⌬B9/Q3 (80)
fVaRQQ (20)
fVaRQQ (60)

fXa saturationa

R2/titrationsb

M

%

95.3
97.6
98.8
99.0
95.3
98.5

Km

0.93–0.95/3
0.9–0.95/3
0.94–0.99/5
0.93–0.97/2
0.90/2
0.95/1

kcat

0.5 ⫾ 0.3
1.63 ⫾ 0.4
9 ⫾ 3.7
12 ⫾ 8.3
0.18 ⫾ 0.04e
0.15 ⫾ 0.04

min

Effective prothrombinase
concentrationc

⫺1

122 ⫾ 16
207 ⫾ 55
487 ⫾ 165
866 ⫾ 480
655 ⫾ 33e
821 ⫾ 51

kcat/Km

pM

⫺1 ⫺1
M 䡠s

9.5
9.8
9.9
9.9
9.5
9.8

4.1
2.1
0.9
1.2
61e
91

⫻ 106

The percent saturation was calculated using a quadratic equation as described under “Experimental Procedures,” using a Kd of 0.73 and 0.92 nM between fV⌬B9/Q3 or
fVaRQQ and fXa, respectively, and 10 pM fXa for all assays.
b 2
R represents the goodness of fit (minimum and maximum) for all titrations to the equation describing Michaelis-Menten kinetics using the software Prism威. Titrations
studied represent three separate graphs (10 measurements/graph) for experiments using 15 and 30 nM fV⌬B9/Q3 and five different titrations (10 measurements/graph) using
60 nM fV⌬B9/Q3.
c
The effective prothrombinase concentrations were obtained by multiplying the fXa concentration used in each titration by the saturation factor.
d
All titrations were performed with five different recombinant fV preparations. These preparations were different from the preparations used to obtain the data shown in
Table 1.
e
Value is from Table 1.
a

We next performed a titration of fXa with fV⌬B9/Q3. An
increase in the concentration of fV⌬B9/Q3 within prothrombinase resulted in an increase in both the Km and the kcat values of
the enzymatic reaction, although the effective enzyme concentration remained approximately constant (Table 2). In addition,
the specificity constant varied very little over a wide range of
concentrations of fV⌬B9/Q3. This fact is obvious when comparing the results obtained with prothrombinase made with 80 nM
fV⌬B9/Q3 with the data obtained by using prothrombinase
assembled with either 15 or 30 nM fV⌬B9/Q3 (Table 2). The
increase in the kcat (Vmax/ET) of the enzymatic reaction
obtained with prothrombinase assembled with fV⌬B9/Q3 that is
concomitant with an increase in Km can be easily explained
(assuming that Km ⬃ Ks) by the fact that at any given point,
under the experimental conditions employed, the effective concentration of free enzyme in solution is maximized when the
enzyme (prothrombinase) is assembled with fV⌬B9/Q3 compared with the concentration of free enzyme in solution when
prothrombinase is assembled with fVaWT (36). As a consequence, at any given time during the reaction as much as possible of prothrombinase assembled with fV⌬B9/Q3 exists in the
unbound form compared with prothrombinase made with
fVaWT. Altogether, the data demonstrate that the stretch of
amino acids 1000 –1008 from the B region of the pro-cofactor
keeps the molecule in a quiescent state.
It is important to note that the Km and kcat values of prothrombinase assembled with fV⌬B9/Q3 vary (increase) with the
concentration of mutant pro-cofactor used in the assay to
assembly prothrombinase (Table 2). At 15 nM fV⌬B9/Q3, the Km
value of prothrombinase for prothrombin is 0.5 M (Table
2), whereas the Km value of prothrombinase assembled with
fVaWT and fVaRQQ under similar conditions is 0.15 and 0.18
M, respectively (Table 1). In the presence of 30 nM fV⌬B9/Q3,
the Km value of prothrombinase for prothrombin is 1.2 M,
and at 60 nM the Km value of prothrombinase for prothrombin is 8 M. Fig. 4 illustrates an assay where the concentration of fVaWT/fVaRQQ/fV⌬B9/Q3 varies between 0 and 15 nM.
Under these conditions, the Km value of prothrombinase
assembled with fV⌬B9/Q3 is 0.5 M, whereas the Km value of
prothrombinase assembled with fVaWT or fVaRQQ is 0.15
and 0.18 M, respectively. Thus, considering the MichaelisMenten Equation 5,
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V max 䡠 S
Km ⫹ S

冊

(Eq. 5)

in the presence of prothrombinase assembled with fV⌬B9/Q3
(with prothrombin used at 1.4 M, which is ⬃3 Km), the rate of
the reaction is 75% (⫾10%) of the maximum rate. Any further
increase in S gives only a marginal increase in the rate of the
reaction. In the case of prothrombinase assembled with fVaRQQ
(with prothrombin used at 1.4 M, which is ⬃7 Km), the rate of
the reaction is 87% of the maximum rate, although a similar
calculation using fVaWT reveals that the rate of the reaction is
90% of the maximum rate (Vmax). Thus, any small variation in
the interaction of prothrombinase with prothrombin (Km
⬃0.15– 0.5 M) is rendered meaningless because all species are
incubated with an excess amount of prothrombin (1.4 M). As a
result, the binding assay comparing all prothrombinase
enzymes tested in Fig. 4 is kinetically sound and provides compelling data on the fV/fVa-fXa association because the enzymes
assembled with various forms of recombinant fV/fVa molecules work at similar rates.
Our assumption thus far is that fV⌬B9/Q3 within each mixture
remains intact for the duration of the experiments. However,
during the experiments reported above, we are assessing the
fV⌬B9/Q3 interaction with fXa in the presence of membranebound fXa in an assay that measures thrombin formation.
Although we are using an excess of a specific thrombin inhibitor, and although all fV activation cleavage sites are changed to
glutamine, it is important to assess the integrity of the fV⌬B9/Q3
molecule within the mixture containing all reagents, prior to
and at the end of the experiment to verify for any incidental
cleavage and/or activation of the molecule during the experiments. Fig. 5 shows the appropriate control experiments. The
data demonstrate that although fV⌬B9 is indeed activated during the course of the assay (Fig. 5, panel D, lane 2), fV⌬B9/Q3
remains intact during the entire duration of the experiment
(Fig. 5, panel E, lane 2). A direct comparison of the data shown
in Fig. 4 (open and closed squares) with the data illustrated in
Fig. 5 (panel E) demonstrates that the high affinity interaction
between fV⌬B9/Q3 and fXa can only be attributed to the deletion
of amino acid region 1000 –1008, because fVQ3 under similar
experimental conditions has no measurable affinity for fXa. It is
noteworthy that although a 20-fold lower KD(app) value of fVQ3
VOLUME 288 • NUMBER 52 • DECEMBER 27, 2013

Dynamic Regulatory Effects of Specific Factor V Amino Acids

FIGURE 5. Analyses of back activation of wild type fV and recombinant fV
molecules within a prothrombinase assay. fVaWT, fVa⌬B9, fV⌬B9, fVaRQQ, and
fV⌬B9/Q3 were incubated in a prothrombin activation assay mixture before
(lane 1) and 1 h after (lane 2) the addition of fXa as described under “Experimental Procedures.” The reaction was stopped as described under “Experimental Procedures.” After SDS-PAGE and transfer to a PVDF membrane, fV
fragments were detected using monoclonal antibodies ␣HFVaHC17 and
␣HFVaLC9 recognizing the heavy chain (HC) and light chain (LC), respectively.
At right, the positions of fV and the heavy and light chains of fVa are shown.

for plasma-derived fXa is reported in Table 1, the goodness of
fit to the equation describing the one binding site model is very
low (R2 of 0.37, Table 1) suggesting that under the experimental
conditions used fVQ3 most likely does not interact with fXa.
Overall, the data clearly indicate that the high affinity specific
interaction between fV⌬B9/Q3 and fXa is a direct consequence of
the deletion of the nine amino acids from the B region of the
pro-cofactor.
Subsequently, we evaluated the recombinant fV/fVa molecules for their ability to assemble in prothrombinase and activate prothrombin under similar experimental conditions (saturating fV/fVa concentrations with respect to fXa (⬎98%)).
Table 1 shows all kinetic constants derived directly from the
fitted data for each set of titrations (Fig. 6). Prothrombinase
assembled with saturating concentrations of recombinant
fV⌬B9/Q3 (60 nM, ⬎98% saturation) had a Km value that was
57-fold higher than the Km value of prothrombinase assembled
with saturating concentrations of either fVaplasma or fVaWT (20
nM, ⬎98% saturation) for prothrombin (Table 1). In contrast,
under the conditions employed, the kcat (turnover number) of
prothrombinase assembled with fV⌬B9/Q3 was decreased by a
modest 4-fold (Table 1) resulting in an overall 252-fold
decrease of the specificity constant of the reaction when compared with the specificity constant obtained with prothrombinase assembled with fVaWT (Table 1). This particular phenomenon occurring when Km ⬎ [S], so that the ES complex is at a
higher energy level than [E] ⫹ [S], has been already described
(36, 38) and demonstrates that, under these precise conditions,
the Vmax of an enzymatic reaction increases as the interaction of
the substrate with the enzyme becomes weaker in the transition
state (Table 2) (36, 38, 50). This fact is obvious when using the
values provided in Table 1 and Equation 3. A difference in transition state free energy of 3.3 kcal/mol can be observed between
prothrombinase assembled with fV⌬B9/Q3 and prothrombinase
DECEMBER 27, 2013 • VOLUME 288 • NUMBER 52

FIGURE 6. Determination of kinetic parameters of prothrombinase
assembled with various fV/Va species. Initial rates of thrombin generation
were determined using the KD(app) for fXa found in Fig. 4 to determine the
concentration of fVa necessary to obtain over 98% fXa saturation as described
under “Experimental Procedures” in the presence of PCPS vesicles and fXa
(32, 33). Data for prothrombinase assembled with fVaWT are shown by filled
circles (20 nM, 98.6% fXa saturation). Data for prothrombinase assembled with
60 nM fV⌬B9/Q3 are depicted by filled squares (98% fXa saturation), and data for
prothrombinase assembled with 80 nM fV⌬B9/Q3 are depicted by open inverse
triangles (99% fXa saturation). Data for prothrombinase assembled with
fVaRQQ are shown by filled diamonds. The titration shown with 60 nM fV⌬B9/Q3
is the average of results from experiments performed with five different preparations of purified recombinant protein, although the titration with 80 nM
fV⌬B9/Q3 is the average from two different preparations of recombinant protein. The kinetic constants were derived directly from the plotted data and are
reported in Tables 1 and 2.

assembled with fVaWT consistent with a strong interaction
between the latter enzyme and prothrombin in the transition
state. Interestingly, although the kcat of prothrombinase assembled with fVaRQQ is modestly decreased by 3-fold, the Km value
of the reaction is similar to the Km value obtained with fVaWT,
resulting in an overall 3-fold decrease in the specificity constant
of the enzyme (Table 1). The ratio of the kcat/Km between prothrombinase assembled with fVaRQQ and prothrombinase
made with fVaWT (Table 1) from Equation 4 corresponds to a
modest difference in transition state free energy of 0.81 kcal/
mol, suggesting that there is no significant difference in the
binding of the transition state intermediate between prothrombinase assembled with fVaWT and prothrombinase made with
fVaRQQ. Thus, like prothrombinase made with fVaWT, prothrombinase assembled with fVaRQQ established a strong interaction with the substrate in the transition state resulting in
similar (low) Km values. A simple comparison of the data
obtained with prothrombinase assembled with fVaWT, fVaRQQ
(Table 2), or fVQ3 demonstrates that under similar experimental conditions the cleavage at Arg709 alone is required and sufficient to promote optimum interaction of prothrombin with
prothrombinase (lower Km).
Visualization of the Activation Pathway—Our findings thus
far specify that fV⌬B9/Q3 is fully able to bind the enzyme fXa
with high affinity and induce clotting in fV-deficient plasma.
Prothrombinase assembled with fV⌬B9/Q3 is also capable of
activating prothrombin with a kcat (Vmax/ET) that is only 4-fold
slower than the kcat for the reaction produced by prothrombiJOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 7. SDS-PAGE analyses of prothrombin-activated fragments by prothrombinase assembled with various recombinant molecules. Panel A,
plasma-derived prothrombin (1.4 M) was activated by prothrombinase assembled with fVaWT (final concentration of 20 nM, 96.6% fXa saturation); panel B,
prothrombinase assembled with fV⌬B9/Q3 (final concentration of 60 nM, 99% fXa saturation). Aliquots were withdrawn at various time intervals and treated as
described (18, 40). M represents the lane with molecular weight markers (from top to bottom): 98,000, 64,000, 50,000, and 36,000, respectively. Lanes 1–19 show
samples from the reaction mixture before (0 min) the addition of fXa and 20, 40, 60, 80, 100, 120, 140, 160, 180, 200, 220, and 240 s and 5, 6, 10, 20, 30, and 60
min, respectively, after the addition of fXa. Positions of prothrombin-derived fragments are shown to the right of panel B.

nase assembled with fVaWT. However, in an assay using purified reagents, there is a substantial increase in the MichaelisMenten constant (Km) of prothrombinase assembled with
fV⌬B9/Q3 compared with prothrombinase assembled with
fVaWT. To better understand these results and to establish if
there is a defect in the pathway for prothrombin activation by
prothrombinase assembled with fV⌬B9/Q3, we studied prothrombin activation by gel electrophoresis (Fig. 7).
The results demonstrate a modest delay in plasma prothrombin activation by prothrombinase assembled with fV⌬B9/Q3 as
compared with the activation of prothrombin by prothrombinase assembled with fVaWT (Fig. 7). These data are in complete
accord with the kinetic data. Scanning densitometry of the gels
shown in Fig. 7 demonstrated a 1.5-fold delay in prothrombin
consumption by prothrombinase assembled with fV⌬B9/Q3 as
compared with the consumption of prothrombin by prothrombinase assembled with fVaWT (Fig. 8). In addition, when prothrombin is activated by prothrombinase assembled with
fV⌬B9/Q3, there is slight persistence (lingering) of meizothrombin throughout the activation process that is accompanied by a
small delay in thrombin formation (Fig. 7B).
To understand the effect of the nine amino acid deletion on
the ability of prothrombinase assembled with fV⌬B9/Q3 to
cleave and activate prothrombin, we compared the rates of prothrombin consumption by prothrombinase assembled with
fV⌬B9/Q3 to the rate of prothrombin consumption by prothrombinase assembled with fVaRQQ that has a kcat value comparable with prothrombinase assembled with the mutant cofactor and a Km value similar to prothrombinase assembled with
fVaWT, using similar experimental conditions (60 nM fV⌬B9/Q3
and 80 nM fVaRQQ). The kinetic data are shown in Table 2, and
the analysis of the time course is provided in Fig. 8 and shows
that prothrombin consumption by prothrombinase assembled
with fVaRQQ is similar to the rate of prothrombinase assembled
with fV⌬B9/Q3 (12.7 and 14 mol of prothrombin consumed per
s/mol of factor Xa, respectively). This result is expected because
the kcat value of prothrombinase assembled with either
fV⌬B9/Q3 (80 nM) or fVaRQQ (60 nM) is similar (Table 2). The
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rate of prothrombin consumption by prothrombinase assembled with fVaWT was 21 mol of prothrombin consumed per
s/mol of factor Xa. These data demonstrate that prothrombinase assembled with fV⌬B9/Q3 has a similar capability to function as prothrombinase assembled with fVaRQQ, even though
the specificity constant of the enzyme for prothrombin is substantially lower (Table 1).
To verify which cleavage in prothrombin is specifically
affected by prothrombinase assembled with fV⌬B9/Q3, we used
recombinant prothrombin molecules that have only one cleavage site for prothrombinase (at Arg320 for rMZ-II and at Arg271
for rP2-II, data not shown) (24). The data demonstrate a small
difference between the rates of activation of rMZ-II by prothrombinase assembled with fV⌬B9/Q3 as compared with the
rates of rMZ-II activation by prothrombinase made with
fVaWT. No significant difference was observed when rP2-II was
incubated with prothrombinase assembled with fV⌬B9/Q3 as
compared with cleavage of rP2-II by prothrombinase assembled with fVaWT. These data confirm our findings obtained
with plasma-derived prothrombin. Overall, the data demonstrate that the rate of prothrombinase-mediated cleavage at
Arg320 in prothrombin is slightly affected by prothrombinase
assembled with fV⌬B9/Q3.
To determine the effect of deleting nine amino acids from the
B region of fV on the cleavage of prothrombin at Arg271 alone,
we compared the rate of cleavage of FPR-meizothrombin by
prothrombinase assembled with either fVaWT or fV⌬B9/Q3 (data
not shown). The data demonstrate a 1.8-fold delay for cleavage
of FPR-meizothrombin at Arg271 by prothrombinase assembled with fV⌬B9/Q3 as compared with the same reaction catalyzed by prothrombinase assembled with fVaWT. Thus, the nine
amino acid deletion in fV⌬B9/Q3 does not have a large inhibitory
effect on prothrombinase cleavage at Arg271. Overall, these data
strongly suggest that amino acid region 1000 –1008 represents
a crucial regulatory amino acid stretch because it covers the
important binding site(s) of fVa for fXa. The large increase in
the Km value of the enzymatic reaction using prothrombinase
assembled with fV⌬B9/Q3 is most likely due to the steric hinVOLUME 288 • NUMBER 52 • DECEMBER 27, 2013
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FIGURE 8. Analysis of prothrombin consumption by prothrombinase assembled with recombinant fV/fVa molecules. The two gels shown in Fig. 7 were
scanned, and prothrombin consumption was recorded as described under “Experimental Procedures.” Following scanning densitometry, the data representing prothrombin consumption as a function of time (seconds) were plotted using nonlinear regression analysis according to the equation representing a
first-order exponential decay using the software Prism姞. The apparent first-order rate constant, k (s⫺1), was obtained directly from the fitted data. Prothrombinase was assembled with recombinant fVaWT (filled circles), fV⌬B9/Q3 (filled squares), and factor VaRQQ (gel not shown in Fig. 7, filled triangles).

drance by the bulky B region still attached to the heavy chain of
the cofactor.

DISCUSSION
The data presented herein demonstrate for the first time that
the basic amino acid region composed of residues 1000 –1008
and located in the middle portion of the B domain of fV is a
dynamic regulator for the binding of the active cofactor to fXa
within prothrombinase. We have shown that three out of the
six amino acid residues from the heavy chain of fVa that are
involved in fXa binding are acidic in nature (17, 18, 22, 34, 51).
Our previous work with recombinant fVa molecules containing
specific point mutations of these amino acids demonstrates a
significant decrease in affinity for fXa when the residues were
mutated two by two and a dramatic decrease in affinity (50fold) when four amino acids were mutated simultaneously (17,
18). It is thus logical to hypothesize that in the absence of injury
to the endothelium these acidic amino acids interact with the
1000 –1008 region from the B domain of fV to neutralize the
unnecessary interaction of the pro-cofactor with fXa (Fig. 9).
Upon vascular injury and thrombin formation, this region is
removed following proteolytic cleavage. To the best of our
knowledge, this is the first time that this part of the molecule
alone has ever been functionally investigated with a full-length
recombinant fV molecule.
Previous work using recombinant B domainless factor V suggested that two regulatory sequences of 45 and 44 amino acids
each (963–1008 and 1492–1538, respectively) are required to
keep the pro-cofactor in a quiescent state (14, 15, 49). The
requirement for these two sequences was deduced from experDECEMBER 27, 2013 • VOLUME 288 • NUMBER 52

FIGURE 9. Schematic interpretation of the data. In full-length fV, the basic
amino acid region 1000 –1008 from the B domain (blue) covers the fXa-binding site(s) located on the A2 and A3 of the molecule (yellow). The acidic 680 –
709 region is shown in purple. From the kinetic and binding data obtained, we
can hypothesize that fV⌬B9/Q3 and fVaRQQ are able to have a productive interaction with prothrombin because both the fXa and prothrombin-bindings
sites are available.

iments comparing several B domainless molecules where large
amino acid portions of the B domain were either added or
deleted to a recombinant fV molecule lacking most of the B
domain (680 amino acids) (14). Conclusions were based on
results from experiments using clotting activities, direct binding assays, and primary thrombin generation plots using preJOURNAL OF BIOLOGICAL CHEMISTRY
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thrombin-2 or prothrombin as substrates. No kinetic studies of
the mutant molecules were provided (15, 49). In addition,
although earlier data showed that amino acid region 963–1008
alone was required to keep the pro-cofactor in a quiescent state
(15), more recently Bos and Camire (49) showed that, in addition to region 963–1008, amino acid region 1492–1538 was also
necessary to keep the pro-cofactor in an inactive state. Moreover, a construct without sequence 1000 –1008 (FV-956 (15))
was shown to have clotting activity comparable with a recombinant molecule harboring this biologically important stretch
of amino acids (FV-B8-BR3 (49)). Results presented herein
were obtained using minimally altered full-length recombinant
fV, are in sharp contrast with those conclusions, provide a
detailed kinetic and thermodynamic analysis of the results
obtained with each full-length recombinant fV mutant, and
identify a short amino acid stretch from the B domain of the
pro-cofactor as the only amino acid sequence required to keep
fV in a quiescent state. Our work using minimally modified
full-length recombinant fV provides a new physiological role
for this basic region. Specifically, amino acid region 1000 –1008
has the ability to maintain the pro-cofactor in a latent state by
impairing its interaction with fXa (Fig. 9).
Prothrombinase is an enzymatic complex composed of two
subunits as follows: a catalytic subunit (fXa) and a regulatory
subunit (fVa) assembled on a procoagulant membrane surface
in the presence of divalent metal ions. The catalytic subunit
alone can cleave and activate prothrombin; however, the rate of
thrombin formation is slow and incompatible with survival.
Addition of phospholipid vesicles increases the Vmax of the
reaction by a modest 7-fold, whereas the Km of fXa is increased
by 380-fold (52). Addition of fVa to the phospholipid/fXa mixture has no significant effect on the Km value of the enzyme, but
it increases the Vmax of the enzymatic reaction by ⬃3000-fold.
Thus, the fXa-fVa interaction mostly affects the catalytic efficiency of the enzymatic reaction (kcat, turnover number)
toward prothrombin and demonstrates that fVa is required for
the efficient prothrombin to thrombin formation by fXa. As a
consequence, fVa’s contribution to prothrombinase once
bound to fXa is most likely materialized by positioning prothrombin in an optimal orientation for efficient fXa cleavage
and timely thrombin formation. We and others have repetitively demonstrated that the heavy chain of fVa, and in particular the COOH-terminal acidic region of the heavy chain of
fVa, immediately adjacent to the cleavage site at Arg709, is
required for optimal rates of prothrombin cleavage and thrombin formation (41, 42, 53). Our present data clearly demonstrate that amino acid sequence 1000KTRKKKKEK1008, containing a cluster of basic amino acids, appears to control
spontaneous binding of fV to fXa. This stretch of amino acids
being ionic in nature is most likely found on the surface of the
full-length derivative, is exceedingly conserved among species
(Fig. 2), providing further proof to its fundamental purpose in
coagulation, and is in close proximity to a thrombin cleavage
site.
We show that fV⌬B9/Q3 can act as a cofactor for the increase
in prothrombinase activity as compared with fXa alone with
respect to prothrombin cleavage, albeit with a decreased kcat
(Table 2). However, increasing the concentration of fV⌬B9/Q3
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within the mixture results in an increased kcat value (Vmax/ET)
because of the increase in the number of productive collisions
between prothrombinase assembled with fV⌬B9/Q3 and prothrombin. The increase in kcat is not due to the increase in
enzyme concentration, because the concentration of prothrombinase remains essentially constant over a large increase
in fV⌬B9/Q3 concentration (15– 80 nM, Table 2). However,
increasing the concentration of fV⌬B9/Q3 also results in an
increase in the Km value of the reaction. Thus, it is logical to
hypothesize that most likely an excess concentration of the
bulky B domain still attached to the end of the heavy and light
chains of the cofactor impairs prothrombin interaction with the
enzyme in a competitive manner with respect to prothrombin.
Removal of the nine basic amino acids from the B region had
a highly significant effect on the dissociation constant of
recombinant fV⌬B9/Q3 for fXa when compared with fVQ3. We
have measured the KD(app) of fV⌬B9/Q3 for factor Xa under physiological concentrations of fV (1–10 nM). Under these conditions, the Km value of prothrombinase assembled with fV⌬B9/Q3
is similar to the Km value of prothrombinase assembled with
fVaWT (Fig. 4 and Tables 1 and 2). Increasing the concentration
of the mutant pro-cofactor within prothrombinase, while keeping fXa constant, resulted in increased Km and kcat values of the
enzyme (Table 2). As a consequence, even though the Km value
of prothrombinase assembled with the mutant pro-cofactor
was significantly increased in an in vitro assay utilizing a chromogenic substrate and much higher (saturating) supraphysiological concentrations of fV⌬B9/Q3 (60 nM), suggesting
impaired interaction between prothrombinase assembled with
high concentrations of fV⌬B9/Q3 and prothrombin, the clotting
activity of fV⌬B9/Q3, which is a measure of its physiological
activity in vivo (because clotting requires very little active cofactor (54, 55)), was indistinguishable from the clotting activities of
fVaWT or fVaplasma. These results were verified by performing
similar experiments using high concentrations of fVaRQQ.
Thus, under physiological conditions fV⌬B9/Q3 can promote
efficient thrombin generation, which in turn will result in efficient fibrin clot formation. Because it has been well established
that even minute concentrations of fVa (0.1%) in mice provide
rescuing effects on physiology (56, 57), it therefore becomes
obvious that even a small mutation (one amino acid) within the
1000 –1008 region of the B domain could have profound and
devastating clinical implications for normal hemostasis. This
may be the reason that to date there are no documented occurrences of a mutation in this precise highly basic and conserved
stretch of amino acids because any amino acid alteration in this
region is incompatible with survival.
It is important to note that to test the overall function of the
recombinant pro-cofactor, functional assays alone are insufficient in obtaining a definitive answer as to the exact function of
a region of the pro-cofactor on prothrombinase function and
need to be coupled with experiments employing SDS-gel electrophoresis that provide for a visual inspection of the activation
pathways of prothrombin. We have observed an ⬃250-fold
decrease in the substrate specificity of prothrombinase assembled with fV⌬B9/Q3, in the presence of three times the physiological concentration of fVa, which was due mostly to its
inability to interact with prothrombin. In contrast, using physVOLUME 288 • NUMBER 52 • DECEMBER 27, 2013
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iological concentrations of recombinant molecules, we show
that fVQ3 had impaired clotting activity and did not show any
interaction with fXa compared with the ability of fVaplasma,
fVaWT, fVaRQQ, and recombinant fV⌬B9/Q3 molecules.
Although fV⌬B9/Q3 had similar clotting activity as the activated
wild type cofactor molecule, the recombinant protein is completely resistant to cleavage and activation by thrombin as seen
with fVQ3. Altogether, these data validate our results obtained
with fV⌬B9/Q3 and suggest that this peptide sequence composed
of mostly basic amino acids is indispensable in preventing
unwanted clot formation.
Activation studies of fV and the analysis of the function of the
B domain are crucial because the penultimate step of the common pathway during blood clotting is the assembly of prothrombinase, which is necessary for thrombin formation. Our
data provide a logical explanation for the sequential cleavage
and activation of human fV by thrombin. Initial cleavage at
Arg709 is necessary to expose both the COOH-terminal portion
of fVa heavy chain necessary for optimal prothrombin interaction and the fXa-binding site (Fig. 9). Cleavages at Arg1018 and
Arg1545 release additional constraints on the pro-cofactor that
can then fully interact with fXa and efficiently produce thrombin. Results from this project provide a unique role for the B
domain residues in fV involved in the regulation of its coagulant
cofactor effects. Further experiments involving alanine scanning mutagenesis in full-length recombinant fV will provide
concrete insights into the identity of the specific amino acids
within the 1000 –1008 region that inhibit fXa binding. This
study provides significant new and original information of a
commanding stretch of amino acids that could be used in creating safer alternative therapies for thrombotic and/or hemophilic patients by synthesizing molecules targeting a regulatory
sequence within fV that is not currently in existence.
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